Unknown

Dataset Information

0

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.


ABSTRACT: Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by in silico screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis.

SUBMITTER: Luo LX 

PROVIDER: S-EPMC6071735 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Identification of mitoxantrone as a new inhibitor of ROS1 fusion protein in non-small cell lung cancer cells.

Luo Lian-Xiang LX   Fan Xing-Xing XX   Li Ying Y   Peng Xia X   Ji Yin-Chun YC   Hsiao Wendy Wen-Luan WW   Liu Liang L   Leung Elaine Lai-Han EL   Yao Xiao-Jun XJ  

MedChemComm 20170126 3


Mitoxantrone, an FDA-approved drug for multiple sclerosis and hormone refractory prostate cancer, is identified as a potent inhibitor of ROS1 fusion protein by <i>in silico</i> screening in non-small cell lung cancer cells. Mitoxantrone can suppress the phosphorylation of ROS1 and subsequently inhibit its downstream signaling pathway and thus induce cell apoptosis. ...[more]

Similar Datasets

| S-EPMC6312842 | biostudies-other
| S-EPMC7458663 | biostudies-literature
| S-EPMC8590892 | biostudies-literature
| S-EPMC6071718 | biostudies-literature
| S-EPMC7400592 | biostudies-literature
| S-EPMC9081178 | biostudies-literature
| S-EPMC4483477 | biostudies-literature
| S-EPMC4264527 | biostudies-literature
| S-EPMC7811790 | biostudies-literature
| S-EPMC5694459 | biostudies-literature